VOR Stock Analysis: Buy, Sell, or Hold?
VOR - Vor Biopharma Inc. Common Stock
$23.36
0.29 (1.28%)
â˛
5d:
+1.43%
30d:
+23.08%
90d:
+55.32%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When VOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: VOR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: VOR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: VOR is currently trading at $23.36, which is considered slightly high relative to its 30-day fair value range of $19.18 to $23.39.
Technical Outlook: Technically, VOR is in a strong uptrend. Immediate support is located at $21.75, while resistance sits at $24.54.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $39.00 (+67.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VOR is in a strong uptrend. Immediate support is located at $21.75, while resistance sits at $24.54.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $39.00 (+67.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$19.18 -
$23.39
Company Quality Score
48/100
(HOLD)
Options IV Signal
14th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
73.8%
All Signals
- BULLISH: Options cheap (IV 14th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 67.0% below Wall St target ($39.00)
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$19.18 -
$23.39
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$3.58
(15.3%)
Support & Resistance Levels
Support Level
$21.75
Resistance Level
$24.54
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.45
Wall Street Target
$39.00
(+67.0%)
Share & Embed Analysis
Last updated: August 23, 2026 10:32 PM ET
Data refreshes hourly during market hours. Next update: 11:32 PM
Data refreshes hourly during market hours. Next update: 11:32 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Ra Capital Management, LâĻ
SELL
165150 shares
2026-04-22
Ra Capital Management, LâĻ
SELL
171963 shares
2026-04-20
Ra Capital Management, LâĻ
SELL
458411 shares
2026-04-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
